John Thomas Feutrill

This inventor holds 8 USPTO granted patents. Top assignee: Kala Pharmaceuticals, Inc.. Active years: 2017-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Thomas Feutrill. Retrieved from https://idiyas.com/inventor/john-thomas-feutrill-5xeu4is7

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8

% Patents Active = 62.5

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 8(Granted Patents)

Location History:

Waltham, MA (US) (2017 - 2019)
Watertown, MA (US) (2020 - 2022)

Company Filing History:

8 out of 53

Kala Pharmaceuticals, Inc.

patents

Years Active: 2017-2022

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11352343 - Urea derivatives and uses thereof (2022-06-07),

2. 10723719 - Urea derivatives and uses thereof (2020-07-28),

3. 10329280 - Urea derivatives and uses thereof (2019-06-25),

4. 10316022 - Urea derivatives and uses thereof (2019-06-11),

5. 10059693 - Urea derivatives and uses thereof (2018-08-28),

6. 10059692 - Urea derivatives and uses thereof (2018-08-28),

7. 9802922 - Urea derivatives and uses thereof (2017-10-31),

8. 9580421 - Urea derivatives and uses thereof (2017-02-28),

Title: John Thomas Feutrill: Innovator in Pharmaceutical Compounds

Introduction

John Thomas Feutrill is a notable inventor based in Waltham, MA (US), recognized for his contributions to the field of pharmaceuticals. He holds a total of 8 patents, showcasing his innovative approach to developing novel compounds and their applications in treating various diseases.

Latest Patents

Feutrill's latest patents focus on urea derivatives and their uses. These inventions provide novel compounds that are designed to penetrate mucus and are aimed at treating and preventing diseases associated with abnormal angiogenesis and aberrant signaling of growth factors, such as vascular endothelial growth factor (VEGF). His work addresses a range of proliferative diseases, including cancers and ocular diseases like macular degeneration and glaucoma. The patents also include methods and kits for utilizing these compounds effectively in clinical settings.

Career Highlights

Feutrill is currently associated with Kala Pharmaceuticals, Inc., where he continues to push the boundaries of pharmaceutical innovation. His work has significant implications for the treatment of various diseases, making him a key figure in the industry.

Collaborations

Feutrill collaborates with talented individuals such as Winston Zapanta Ong and Pawel Wojciech Nowak, contributing to a dynamic research environment that fosters innovation and development.

Conclusion

John Thomas Feutrill's contributions to pharmaceutical inventions highlight his commitment to advancing medical science. His innovative work in developing urea derivatives is paving the way for new treatments that could significantly impact patient care.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]